Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 150 of 285 entries
View as:

Efficacy and Safety of Entecavir Maleate Tablets in Chinese Patients With Hepatitis B

Phase: N/A Priority: Normal
NCT ID: NCT01926288 Org: User:
Start: 10/31/08 End: 03/31/14 Due: 03/31/15

Study of Obeticholic Acid（OCA） Combination With Ursodeoxycholic Acid (UDCA) in Patients With Primay Biliary Cirrhosis (PBC)

Phase: N/A Priority: Normal
NCT ID: NCT04956328 Org: User:
Start: 07/22/21 End: 09/20/23 Due: 09/20/24

Salmeterol Xinafoate and Fluticasone Propinate Powder for Inhalation for Asthma

Phase: N/A Priority: Normal
NCT ID: NCT03461627 Org: User:
Start: 04/01/17 End: 10/31/18 Due: 10/31/19

TQB2916 Injection Combined With Chemotherapy or Penpulimab Injection in the Treatment of Solid Tumors

Phase: N/A Priority: Normal
NCT ID: NCT06500091 Org: User:
Start: 07/31/24 End: 12/31/26 Due: 12/31/27

Phase II Study of Anlotinib Versus Sunitinib in Patients With Advanced Renal Cell Carcinoma（RCC）

Phase: N/A Priority: Normal
NCT ID: NCT02072031 Org: User:
Start: 12/31/13 End: 12/31/16 Due: 12/31/17

Drug-Drug Interaction (DDI) Study for TQB3616

Phase: N/A Priority: Normal
NCT ID: NCT06662773 Org: User:
Start: 11/30/24 End: 07/31/25 Due: 07/31/26

Bioequivalence Study of Mesylate Imatinib Capsule in Chronic Myeloid Leukemia Body

Phase: N/A Priority: Normal
NCT ID: NCT01795716 Org: User:
Start: 09/30/12 End: 06/30/13 Due: 06/30/14

A Study of AL2846 Capsule Combined With Standard Chemotherapy Regimen in Subjects With Advanced Colorectal Cancer

Phase: N/A Priority: Normal
NCT ID: NCT04337879 Org: User:
Start: 07/20/20 End: 12/31/20 Due: 12/31/21

A Study of TQB2450 Injection and Anlotinib Hydrochloride Capsules to Treat Triple Negative Breast Cancer (TNBC)

Phase: N/A Priority: Normal
NCT ID: NCT03855358 Org: User:
Start: 05/09/19 End: 12/30/20 Due: 12/30/21

Material Balance Study of TQ-B3525

Phase: N/A Priority: Normal
NCT ID: NCT05675202 Org: User:
Start: 01/31/23 End: 12/31/23 Due: 12/31/24

A Clinical Trial of TQA3038 Injection in Healthy Adult Subjects

Phase: N/A Priority: Normal
NCT ID: NCT06085053 Org: User:
Start: 11/30/23 End: 12/31/25 Due: 12/31/26

A Study of TQ-B3525 on Tolerance and Pharmacokinetics

Phase: N/A Priority: Normal
NCT ID: NCT03510767 Org: User:
Start: 06/20/18 End: 08/31/24 Due: 08/31/25

A Study of Anlotinib Hydrochloride Capsules in Subjects With Diffuse Large B-Cell Lymphoma

Phase: N/A Priority: Normal
NCT ID: NCT04827004 Org: User:
Start: 04/30/21 End: 12/31/22 Due: 12/31/23

Study to Evaluate the Tolerability, Safety, Pharmacokinetics and Pharmacodynamics of TQA3810 Tablets

Phase: N/A Priority: Normal
NCT ID: NCT06431438 Org: User:
Start: 10/01/21 End: 11/20/23 Due: 11/20/24

A Clinical Study of TQB2618 Injection Monotherapy and Combination Regimen (With Penpulimab Injection ±Anlotinib Hydrochloride Capsules) in the Four or Later Lines of Treatment of Advanced Colorectal Cancer.

Phase: N/A Priority: Normal
NCT ID: NCT06010901 Org: User:
Start: 01/13/24 End: 07/31/25 Due: 07/31/26

A Study of TQB2930 for Injection Monotherapy or Combination Therapy in Patients With Recurrent/Metastatic Breast Cancer

Phase: N/A Priority: Normal
NCT ID: NCT06202261 Org: User:
Start: 04/13/23 End: 10/31/27 Due: 10/31/28

Pharmacokinetic and Tolerance Study of TQ-A3326 in Healthy Participants.

Phase: N/A Priority: Normal
NCT ID: NCT03714568 Org: User:
Start: 11/11/18 End: 09/30/19 Due: 09/30/20

A Study to Evaluate Drug-Drug Interaction of TQ05105 Tablets

Phase: N/A Priority: Normal
NCT ID: NCT06024915 Org: User:
Start: 09/30/23 End: 12/31/23 Due: 12/31/24

To Predict Efficacy by Detecting Circulating Endothelial Cell Subsets and Blood Perfusion Parameters Changes in Vivo Tumor in the Phase II/III Study of Anlotinib in Patients With Advanced Non-small Cell Lung Cancer

Phase: N/A Priority: Normal
NCT ID: NCT02029209 Org: User:
Start: 12/31/13 End: 03/31/17 Due: 03/31/18

TQ-B3525 Tablets Combined With Osimertinib Mesylate Tablets in the Treatment of Advanced Non-Small Cell Lung Cancer

Phase: N/A Priority: Normal
NCT ID: NCT05284994 Org: User:
Start: 03/11/22 End: 06/30/24 Due: 06/30/25

Study to Investigate the Absorption, Metabolism and Excretion of [14C] Anlotinib in Patients With Advanced Cancer Patients

Phase: N/A Priority: Normal
NCT ID: NCT02622932 Org: User:
Start: 12/02/15 End: 08/31/17 Due: 08/31/18

A Study of TQB2450 Injection Combined With Anlotinib Hydrochloride Capsule as Second-line Treatment in Subjects With Advanced Biliary Cancer

Phase: N/A Priority: Normal
NCT ID: NCT04809142 Org: User:
Start: 02/04/21 End: 02/01/23 Due: 02/01/24

A Clinical Study of TQB3912 Tablets in Patients With Advanced Malignant Tumor

Phase: N/A Priority: Normal
NCT ID: NCT05997342 Org: User:
Start: 08/31/23 End: 08/31/25 Due: 08/31/26

A Phase I Study of TQ-B3456 on Tolerance and Pharmacokinetics

Phase: N/A Priority: Normal
NCT ID: NCT03754244 Org: User:
Start: 09/24/20 End: 02/28/22 Due: 02/28/23

A Study of Sinotecean on Tolerance and Pharmacokinetics

Phase: N/A Priority: Normal
NCT ID: NCT02469883 Org: User:
Start: 03/31/15 End: 12/31/16 Due: 12/31/17